Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19

The COVID-19 pandemic continues worldwide. A prothrombotic state has been associated with COVID-19, however, the pathogenesis remains unclear. Previous studies have reported elevated levels of antiphospholipid (aPL) antibodies in patients with COVID-19 which can lead to prolonged clotting times and thromboembolic events.1,2 It is unclear if these antibodies represent an epiphenomenon or if they are involved in hemostatic abnormalities observed in COVID-19 patients.3 Research has predominantly focused on lupus anticoagulant and other aPL antibodies although information is scarce.